IL6 and polycystic ovary syndrome: EA improved insulin sensitivity in PCOS models, and this efficacy may be associated with increased plasma insulin-like growth factor-I, increased expression of leptin and interleukin-6 (IL-6) and decreased expression of uncoupling protein 2 in visceral adipose tissue (28).